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• The 9vHPV vaccine prevents 98% of high-grade cervical dysplasia related to the 9 HPV types covered by the vaccine.
• The 9vHPV vaccine prevents 98% of cervical surgeries related to the 9 HPV types covered by the vaccine.
• Vaccine did not prevent diseases related to HPV types detected at baseline but reduced diseases related to other HPV types.
• While early vaccination in HPV naïve persons is best, sexually active persons may benefit from catch-up vaccination programs.
• These data will be important to inform future public health vaccination recommendations.☆ Data previously presented at the European Research
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Available online 11 April 2019Objective.Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and cervical surgeries
related to all nine vaccine components was assessed compared with a historic placebo population. This was not
assessed in the 9vHPV vaccine efficacy trial since the trial was quadrivalent HPV (qHPV) vaccine-controlled, ef-
ficacy was measured for the five HPV types covered only by 9vHPV vaccine (HPV31/33/45/52/58), but not the
four types covered by both vaccines (HPV6/11/16/18).
Methods. Three international, randomized, double-blind studies were conducted using the same methodol-
ogy. In the 9vHPV vaccine study (NCT00543543), 7106 and 7109 women received 9vHPV or qHPV vaccine, re-
spectively. In the historic qHPV vaccine studies (FUTURE I [NCT00092521] and II [NCT00092534]), 8810 and
8812women received qHPV vaccine or placebo, respectively, based on the same eligibility criteria. Cervical cyto-
logical testing was performed regularly. Biopsy or definitive therapy specimens were assessed for HPV DNA.
Results. Among women negative for 14 HPV types prior to vaccination, incidence of high-grade cervical dis-
ease (9vHPV, n = 2 cases; placebo, n = 141 cases) and cervical surgery (9vHPV, n = 3 cases; placebo, n =Keywords:
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111A.R. Giuliano et al. / Gynecologic Oncology 154 (2019) 110–117170 cases) related to the nine HPV types was reduced by 98.2% (95% confidence interval [CI], 93.6–99.7) and
97.8% (95% CI, 93.4–99.4), respectively. The 9vHPV vaccine did not prevent disease related to vaccine HPV
types detected at baseline, but significantly reduced cervical, vulvar, and vaginal diseases related to other vaccine
HPV types.
Conclusions. Effective implementation of the 9vHPV vaccine may substantially reduce the burden of HPV-
related diseases and related medical procedures.
Trial registrations: clinicaltrials.gov: NCT00543543, NCT00092521, NCT00092534.1. Introduction
A nine-valent human papillomavirus (9vHPV) vaccine was devel-
oped to provide protection against HPV types 6, 11, 16, and 18 already
covered by the quadrivalent HPV (qHPV) vaccine and the next five
most common oncogenic types associated with cervical cancer world-
wide (types 31, 33, 45, 52, and 58) [1]. Based on the prevalence of the
9vHPV vaccine types in worldwide studies, the 9vHPV vaccine is ex-
pected to prevent approximately 90% of all cervical cancers; 70–85% of
high-grade cervical disease; and 90% of HPV-related vulvar, vaginal,
and anal cancers and genital warts worldwide [2–5]. Based on the
worldwide HPV prevalence and type distribution, the 9vHPV vaccine
is expected to provide an additional 19%, 13%, and 20% reduction in cer-
vical, vulvar, and vaginal cancers compared with the qHPV vaccine [5],
and an additional 30% reduction in high-grade cervical intraepithelial
neoplasia [4]. As such, the 9vHPV vaccine comparedwith the qHPV vac-
cine provides additional protection against a substantial proportion of
disease in women [6]. This additional protection, conferred by the
9vHPV vaccine, has implications for cervical cancer screening guidelines
and cancer reduction expectations in countries that do not have screen-
ing programs but have HPV vaccination programs.
In a clinical trial in women, the 9vHPV vaccine prevented ~97% of
high-grade cervical, vulvar, and vaginal disease associated with HPV
31, 33, 45, 52, and 58, elicited non-inferior antibody responses to HPV
6, 11, 16, and 18 compared with qHPV vaccine, and was generally well
tolerated [7,8]. For ethical reasons, the clinical trial did not have a pla-
cebo arm [9]. Since the trial was controlled with qHPV vaccine, a direct
comparison with an unvaccinated population was not possible. Thus,
the reduction in disease and procedures related to all nine vaccine com-
ponents among pre- and young-adolescent females, as well as sexually
experienced women, is not known. The lack of formal assessment of ef-
ficacy compared with an unvaccinated group has been highlighted in
prior publications as a limitation of previous analyses. These data are
needed to inform public health vaccination recommendations and fu-
ture revisions to cervical cancer screening algorithms in vaccinated
populations.
Here, we present efficacy estimates against cervical, vulvar, and vag-
inal disease caused by all nine vaccine HPV types and prevention of re-
lated cervical surgeries compared with a historic placebo population
(the placebo arm of the qHPV vaccine efficacy trials, FUTURE I, and
FUTURE II [10,11]). Efficacy was assessed in females naïve to 14 HPV
types (i.e. the nine vaccine types and the five next most common
known oncogenic types) at baseline—a population that resembles a
pre-adolescent/adolescent population. In addition, we present 9vHPV
vaccine efficacy estimates among all trial participants, stratified bybase-
line HPV status.
2. Methods
2.1. Clinical studies used in the analyses
Protocol V503-001 (NCT00543543) was a double-blind, qHPV-
vaccine-controlled, dose-ranging, efficacy, immunogenicity, and safety
study of the 9vHPV vaccine in approximately 14,000 women aged
16–26 years. Protocols V501-013 (FUTURE I; NCT00092521) andV501-015 (FUTURE II; NCT00092534) were double-blind, placebo-
controlled, efficacy, immunogenicity, and safety studies of the qHPV
vaccine in approximately 17,600women aged 16–26 years (see Supple-
mentary Appendix). Eligibility criteria were consistent across the three
studies; design details and key primary results have been reported
[7–12].
2.2. Ethics approval
All trials were conducted in accordancewith principles of Good Clin-
ical Practice and were approved by the appropriate institutional review
boards and regulatory agencies [7,8,10,11]. All participants provided
written informed consent prior to study participation in accordance
with local laws and regulations.
2.3. Vaccination and follow-up
Participants received a three-dose regimen of 9vHPV vaccine, qHPV
vaccine, or placebo at Day 1,Month 2, andMonth 6. Pap tests for assess-
ment of cervical abnormalities were collected at Day 1, Month 7, and at
6- to 12-month intervals thereafter for the entire study duration for lab-
oratory analysis. Participants with abnormal Pap test results came for
additional visits and underwent meticulous examination of the cervix
(colposcopy) and collection of tissue samples (biopsy, excision) for
pathological examination to detect potential HPV-related disease. Dur-
ing the collection of cervical cytology samples, an inspection for non-
cervical lesionswasperformed. Examinations of the entire external gen-
italia (including the periurethral, perineal, perianal, and vulvar regions)
were conducted at Day 1, Month 7, and each subsequent study visit. If a
lesion suspected to be HPV-related was observed, it was biopsied. Sev-
eral measures were taken to minimize the risk of missing a lesion: par-
ticipants were screened frequently (every 6 to 12 months) and were
required to receive all of their gynecological care in the context of the
study, including collection of all cytology and tissue samples mandated
per the study protocol. In the very rare cases, when cytology or tissue
samples were collected outside of the context of the study, all efforts
were made to obtain relevant cytology, colposcopy/operative, and pa-
thology reports; biopsy diagnostic slides; and tissue blocks if available.
As a result, it is very unlikely that any high-grade dysplasia or cancer oc-
curring during the study would have been missed. Histologic sections
were first read for clinical management by pathologists at a central lab-
oratory (Diagnostic Cytology Laboratories), who were unaware of
treatment-group assignment and HPV status, and were then read for
endpoint determination by a blinded adjudication panel of four pathol-
ogists. Tissue samples were tested by polymerase chain reaction (PCR)
[13,14] for the 12 HPV types identified as oncogenic by the International
Agency for Research on Cancer (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, and 59) [15], plus HPV 6 and 11, which are responsible for 90% of
genital warts [3]. HPV DNA detection by PCR was considered as a surro-
gate of HPV infection and used to identify participants with active HPV
infection at enrollment and determine HPV infection endpoints, as pre-
viously described [9,11].
Analyses presented here are based on end-of-study data for the
9vHPV vaccine (through the last visit that occurred on March 10,
2014), representing up to 6.0 years of follow-up post-Dose 1 (median:
Table 1
Baseline HPV DNA positivity by trial and vaccine allocation.
9vHPV vaccine program qHPV vaccine program
9vHPV vaccine group
(N= 7106)
qHPV vaccine group
(N= 7109)
qHPV vaccine group
(N= 8810)
Placebo group
(N= 8812)
% (m/n) % (m/n) % (m/n) % (m/n)
Any of 14 HPV types testeda 37.2 (2529/6807) 36.8 (2504/6811) 32.5 (2776/8541) 32.2 (2757/8566)
HPV 6 4.3 (296/6961) 3.9 (270/6970) 4.2 (368/8691) 4.0 (349/8708)
HPV 11 0.5 (38/6959) 0.7 (46/6974) 0.7 (64/8703) 0.6 (55/8720)
HPV 16 10.5 (729/6960) 9.9 (689/6969) 9.0 (781/8681) 8.9 (772/8706)
HPV 18 4.5 (313/6954) 4.4 (303/6960) 3.6 (316/8697) 3.7 (325/8717)
HPV 31 5.4 (374/6962) 5.3 (370/6982) 4.5 (394/8687) 4.4 (387/8712)
HPV 33 2.5 (173/6964) 2.4 (167/6968) 2.1 (183/8698) 2.0 (175/8710)
HPV 35 1.7 (120/6967) 1.5 (105/6975) 1.6 (137/8696) 1.5 (133/8715)
HPV 39 6.1 (425/6962) 4.9 (342/6963) 4.6 (396/8690) 4.6 (402/8709)
HPV 45 2.9 (198/6944) 2.8 (198/6962) 2.2 (192/8694) 2.6 (226/8706)
HPV 51 7.9 (552/6956) 8.2 (568/6956) 7.6 (655/8664) 7.1 (614/8693)
HPV 52 7.0 (484/6960) 6.9 (481/6979) 5.8 (505/8687) 5.5 (481/8714)
HPV 56 10.9 (761/6952) 10.6 (741/6958) 7.8 (674/8685) 7.6 (661/8688)
HPV 58 3.9 (273/6964) 3.8 (267/6967) 3.5 (301/8695) 3.9 (342/8715)
HPV 59 4.5 (316/6953) 4.3 (296/6955) 3.6 (315/8694) 3.7 (326/8705)
HPV, humanpapillomavirus;m, number of subjects positive by PCR to the indicatedHPV type; N, number of subjects randomized to the indicated vaccination group; n, number of subjects
with non-missing PCR results for all of the indicated HPV types; PCR, polymerase chain reaction; qHPV, quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;
9vHPV, nine-valent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine. Percent was calculated as 100 × (m/n).
a HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
112 A.R. Giuliano et al. / Gynecologic Oncology 154 (2019) 110–1174.0 years) [8]. End-of-study data for the FUTURE I and FUTURE II studies
include up to 4.9 years of follow-up post-Dose 1 (average: 3.6 years;
25th and 75th percentiles: 3.5 and 3.9 years, respectively) [16].
2.4. Individual study characteristics
The included trials were identical in most parameters, as they used
the same eligibility criteria and methods to assess study endpoints
(i.e. pathology panel and PCR assay) [17]. However, the following differ-
ences should be noted: FUTURE II required Pap screening every
12 months, whereas the two other trials (V503-001 and FUTURE
I) required Pap screening every 6 months; in V503-001 and FUTURE ITable 2
Effect of 9vHPV vaccine on the reduction in incidence of cervical disease (subjects PCR-negativ
Endpoint
Causal HPV type
9vHPV vaccine (N= 4365)
Observed
cases
Incidence per 10,000 person-years
cases (95% CI)
Subjects contributing to the analysis 4229
Cervical disease, any grade
Any of HPV 6, 11, 16, 18, 31, 33, 45,
52, or 58
4 2.5 (0.7–6.4)
HPV 6 1 0.6 (0.0–3.5)
HPV 11 0 0.0 (0.0–2.3)
HPV 16 0 0.0 (0.0–2.3)
HPV 18 0 0.0 (0.0–2.3)
HPV 31 3 1.9 (0.4–5.5)
HPV 33 0 0.0 (0.0–2.3)
HPV 45 1 0.6 (0.0–3.5)
HPV 52 0 0.0 (0.0–2.3)
HPV 58 0 0.0 (0.0–2.3)
High-grade cervical disease
Any of HPV 6, 11, 16, 18, 31, 33, 45,
52, or 58
2 1.3 (0.2–4.5)
HPV 6 0 0.0 (0.0–2.3)
HPV 11 0 0.0 (0.0–2.3)
HPV 16 0 0.0 (0.0–2.3)
HPV 18 0 0.0 (0.0–2.3)
HPV 31 2 1.3 (0.2–4.5)
HPV 33 0 0.0 (0.0–2.3)
HPV 45 0 0.0 (0.0–2.3)
HPV 52 0 0.0 (0.0–2.3)
HPV 58 0 0.0 (0.0–2.3)
CI, confidence interval; HPV, human papillomavirus; N, number of subjects in the analysis popul
11, 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine.(but not FUTURE II), participants with histologically confirmed, HPV-
related, external genital or vaginal lesions were referred to colposcopy
if the external genital or vaginal biopsies were not obtained during
colposcopy.
2.5. Statistical analysis
Efficacy analyseswere conducted on themodified intention-to-treat
(mITT) population (identical to the population referred to as the ITT
population in some HPV vaccine clinical trial publications
[10,11,16,18]), which comprised participants who received at least
one vaccination and had at least one measurement of efficacy for thee to 14 HPV types at baseline).
Historic placebo (N= 5887)
Reduction in incidence %
(95% CI)
Observed
cases
Incidence per 10,000 person-years
cases (95% CI)
5756
315 159.7 (142.5–178.3) 98.4 (96.0–99.5)
40 20.1 (14.4–27.4) 96.9 (82.5–99.8)
14 7.0 (3.9–11.8) 100 (62.8–100)
128 64.5 (53.8–76.7) 100 (96.5–100)
44 22.1 (16.1–29.7) 100 (90.4–100)
67 33.7 (26.1–42.8) 94.4 (84.0–98.5)
35 17.6 (12.3–24.5) 100 (88.1–100)
13 6.5 (3.5–11.2) 90.4 (43.5–99.5)
62 31.2 (23.9–40.0) 100 (92.4–100)
52 26.2 (19.5–34.3) 100 (91.8–100)
141 71.0 (59.7–83.7) 98.2 (93.6–99.7)
10 5.0 (2.4–9.2) 100 (54.7–100)
1 0.5 (0.0–2.8) 100 (≤ − 999–100)
73 36.7 (28.8–46.2) 100 (93.7–100)
18 9.0 (5.4–14.3) 100 (74.0–100)
32 16.1 (11.0–22.7) 92.2 (71.1–98.7)
17 8.5 (5.0–13.7) 100 (71.9–100)
3 1.5 (0.3–4.4) 100 (−113.3–100)
28 14.1 (9.4–20.4) 100 (85.1–100)
23 11.6 (7.3–17.4) 100 (81.1–100)
ation; PCR, polymerase chain reaction; 9vHPV, nine-valent human papillomavirus (types 6,
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mITT population included participants independent of their HPV DNA
test result at the time of vaccination. Analyses were conducted among
women who were negative to 14 HPV types at baseline (9vHPV, N =
4365; placebo, N = 5887) and among all mITT participants stratified
by baseline HPV positivity.
The efficacy of the 9vHPV vaccine relative to historic placebowas es-
timated by direct comparison, where vaccine efficacy was defined as
100% (1 – [incidence rate in 9vHPV vaccine group/incidence rate in his-
toric placebo]). The 95% confidence interval (CI) for vaccine efficacywas
estimated using an exact method as described by Chen et al. [12]. The
V503-001, FUTURE I, and FUTURE II trials were similarly designed, and
incidence rates of efficacy endpoints were similar between the qHPV
vaccine groups contributed by these studies (Supplementary
Table S1), providing support for the direct comparison of 9vHPV vaccine
with historic placebo.
3. Results
Participant characteristics were similar with respect to
sociodemographic and sexual characteristics across the included trials
[7,10,11]. The mean age (years) was 21.9 in the 9vHPV and 21.8 in the
qHPV vaccine arms of the 9vHPV vaccine trial, and 20.0 in both the
qHPV vaccine and placebo arms of the qHPV vaccine trials (Supplemen-
tary Table S2).Table 3
Effect of 9vHPV vaccine on the reduction in incidence of vulvar and vaginal disease (subjects P
Endpoint
Causal HPV type
9vHPV vaccine (N= 4365)
Observed
cases
Incidence per 10,000 person-years
cases (95% CI)
Subjects contributing to the analysis 4320
Vulvar and vaginal disease, any
grade
Any of HPV 6, 11, 16, 18, 31, 33, 45,
52, or 58
9 5.6 (2.6–10.6)
HPV 6 8 5.0 (2.1–9.8)
HPV 11 1 0.6 (0.0–3.5)
HPV 16 1 0.6 (0.0–3.5)
HPV 18 0 0.0 (0.0–2.3)
HPV 31 0 0.0 (0.0–2.3)
HPV 33 0 0.0 (0.0–2.3)
HPV 45 0 0.0 (0.0–2.3)
HPV 52 0 0.0 (0.0–2.3)
HPV 58 0 0.0 (0.0–2.3)
Vulvar and vaginal condyloma
Any of HPV 6, 11, 16, 18, 31, 33, 45,
52, or 58
8 5.0 (2.1–9.8)
HPV 6 7 4.3 (1.7–8.9)
HPV 11 1 0.6 (0.0–3.5)
HPV 16 0 0.0 (0.0–2.3)
HPV 18 0 0.0 (0.0–2.3)
HPV 31 0 0.0 (0.0–2.3)
HPV 33 0 0.0 (0.0–2.3)
HPV 45 0 0.0 (0.0–2.3)
HPV 52 0 0.0 (0.0–2.3)
HPV 58 0 0.0 (0.0–2.3)
High-grade vulvar and vaginal
disease
Any of HPV 6, 11, 16, 18, 31, 33, 45,
52, or 58
0 0.0 (0.0–2.3)
HPV 6 0 0.0 (0.0–2.3)
HPV 11 0 0.0 (0.0–2.3)
HPV 16 0 0.0 (0.0–2.3)
HPV 18 0 0.0 (0.0–2.3)
HPV 31 0 0.0 (0.0–2.3)
HPV 33 0 0.0 (0.0–2.3)
HPV 45 0 0.0 (0.0–2.3)
HPV 52 0 0.0 (0.0–2.3)
HPV 58 0 0.0 (0.0–2.3)
CI, confidence interval; HPV, human papillomavirus; N, number of subjects in the analysis popul
11, 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine.Baseline HPV DNA positivity in each arm (9vHPV, qHPV, placebo) of
the included trials was comparable (Table 1). HPV 16 positivity ranged
from 8.9% in the placebo group to 10.5% in the 9vHPV vaccine group.
Similar proportions of trial participants were positive for two or more
vaccine HPV types across trial groups (Supplementary Table S3); most
participants were negative to all four qHPV vaccine types
(83.5–85.2%), all five newly included HPV types (82.8–85.4%), and all
9vHPV vaccine types (72.6–75.7%). Only two participants were positive
for all qHPV vaccine types (one in the 9vHPV vaccine arm, and one in
the qHPV vaccine arm), and none were positive for all 9vHPV vaccine
types.
The incidence and percentage reduction of HPV-related disease and
procedures with 9vHPV vaccine versus placebo were initially assessed
among women negative at baseline for 14 HPV types. Cervical disease
of any grade related to the 9vHPV vaccine types was reduced by 98.4%
(95% CI, 96.0–99.5), and high-grade cervical intraepithelial neoplasia
(CIN) by 98.2% (95% CI 93.6–99.7) compared with placebo (Table 2).
Similarly, large reductions in disease related to each of the individual
nine HPV types were observed. In general, no clinically or statistically
significant efficacy against lesions related to non-vaccine HPV types
(HPV 35, 39, 51, 56, and 59)was observed (data not shown). The overall
reduction in vulvar and vaginal disease of any grade was 94.9% (95% CI,
90.4–97.5; Table 3). High efficacy against vulvar and vaginal condylo-
mas was also observed (94.3%; 95% CI, 89.0–97.6). Reduction in high-
grade vulvar and vaginal disease was 100% (95% CI, 85.7–100). VaccineCR-negative to 14 HPV types at baseline).
Historic placebo (N= 5887)
Reduction in incidence %
(95% CI)
Observed
cases
Incidence per 10,000 person-years
cases (95% CI)
5827 –
218 110.3 (96.1–125.9) 94.9 (90.4–97.5)
154 77.5 (65.8–90.8) 93.6 (87.5–97.3)
33 16.5 (11.4–23.2) 96.2 (78.0–99.8)
49 24.5 (18.1–32.4) 97.5 (86.2–99.9)
17 8.5 (4.9–13.6) 100 (72.0–100)
26 13.0 (8.5–19.0) 100 (83.8–100)
4 2.0 (0.5–5.1) 100 (−38.4–100)
5 2.5 (0.8–5.8) 100 (−24.1–100)
21 10.5 (6.5–16.0) 100 (78.8–100)
9 4.5 (2.1–8.5) 100 (47.0–100)
174 87.7 (75.2–101.8) 94.3 (89.0–97.6)
144 72.4 (61.1–85.3) 94.0 (87.8–97.2)
31 15.5 (10.5–22.0) 96.0 (76.2–99.8)
19 9.5 (5.7–14.8) 100 (75.9–100)
14 7.0 (3.8–11.7) 100 (62.9–100)
15 7.5 (4.2–12.4) 100 (66.5–100)
4 2.0 (0.5–5.1) 100 (−38.4–100)
3 1.5 (0.3–4.4) 100 (−112.8–100)
16 8.0 (4.6–13.0) 100 (69.4–100)
7 3.5 (1.4–7.2) 100 (24.9–100)
29 14.5 (9.7–20.8) 100 (85.7–100)
5 2.5 (0.8–5.8) 100 (−24.1–100)
1 0.5 (0.0–2.8) 100 (−∞–100)
24 12.0 (7.7–17.8) 100 (82.1–100)
1 0.5 (0.0–2.8) 100 (−∞–100)
5 2.5 (0.8–5.8) 100 (−24.1–100)
0 0.0 (0.0–1.8) –
0 0.0 (0.0–1.8) –
0 0.0 (0.0–1.8) –
2 1.0 (0.1–3.6) 100 (−331.1–100)
ation; PCR, polymerase chain reaction; 9vHPV, nine-valent human papillomavirus (types 6,
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was similar. Cervical biopsy related to the 9vHPV vaccine types was re-
duced by 95.1% (95% CI, 92.6–97.0) and cervical definitive therapy (loop
electrosurgical excision procedure, conization) by 97.8% (95% CI,
93.4–99.4) (Table 4), with reductions of 91.3–100% and 91.5–100%, re-
spectively, across the individual vaccine types.
Vaccine efficacy and incidence rates compared with placebo were
also assessed by baseline HPV status (Table 5, Supplementary
Table S4). Among women who were negative for all 9vHPV vaccine
types, cervical disease of any grade and high grade related to HPV 6,
11, 16, or 18 was significantly reduced by 99.0% (1.1 versus 106.4/
10,000 person-years) and 100% (0.0 versus 49.4/10,000 person-years),
respectively; cervical disease related to HPV 31, 33, 45, 52, or 58 was re-
duced by 96.9% (3.2 versus 104.3/10,000 person-years; 9vHPV versus
placebo) and 95.3% (2.1 versus 45.8/10,000 person-years; 9vHPV versus
placebo), respectively. The incidence of cervical disease related to HPV
31, 33, 45, 52, or 58 was markedly reduced among women positive at
baseline for HPV 6, 11, 16, or 18 but negative for HPV 31, 33, 45, 52,
and 58 (any grade: 95.1%, 8.3 versus 168.3/10,000 person-years; high
grade, 91.1%; 8.3 versus 93.4/10,000 person-years). Similarly, cervical
disease incidence related to HPV 6, 11, 16, or 18 was significantly re-
duced compared with placebo among women negative at baseline for
HPV 6, 11, 16, and 18 but positive for HPV 31, 33, 45, 52, or 58 (any
grade: 97.4%, 3.9 versus 154.4/10,000 person-years; high grade: 95.8%,
3.9 versus 93.7/10,000 person-years).
Efficacy against vulvar and vaginal disease of any grade was primar-
ily restricted to participants whowere HPV 6-, 11-, 16-, and 18-negative
at baseline (Table 5). A significant reduction in the incidence of vulvar
and vaginal disease was observed among women negative at baseline
to all nine HPV types for lesions related to HPV 6, 11, 16, or 18 (any
grade: 94.9%, 5.3 versus 103.1/10,000 person-years; condyloma:
95.0%, 4.2 versus 85.7/10,000 person-years) and HPV 31, 33, 45, 52, or
58 (any grade: 98.2%, 0.5 versus 29.4/10,000 person-years; condyloma:
100%, 0.0 versus 20.0/10,000 person-years).
Reductions in the incidence of biopsy (95.8%) and definitive therapy
(100%) were observed for HPV 6-, 11-, 16-, or 18-related lesions as wellTable 4
Effect of 9vHPV vaccine on the reduction in incidence of cervical biopsy and definitive therapy
Endpoint
Causal HPV type
9vHPV vaccine (N = 4365)
Observed
Cases
Incidence per 10,000 person-years
cases (95% CI)
Subjects contributing to the analysis 4229
Biopsy
Any of HPV 6, 11, 16, 18, 31, 33, 45,
52, or 58
21 13.1 (8.1–20.0)
HPV 6 4 2.5 (0.7–6.4)
HPV 11 0 0.0 (0.0–2.3)
HPV 16 4 2.5 (0.7–6.4)
HPV 18 4 2.5 (0.7–6.4)
HPV 31 7 4.4 (1.8–9.0)
HPV 33 0 0.0 (0.0–2.3)
HPV 45 2 1.2 (0.2–4.5)
HPV 52 3 1.9 (0.4–5.5)
HPV 58 0 0.0 (0.0–2.3)
Definitive therapy
Any of HPV 6, 11, 16, 18, 31, 33, 45,
52, or 58
3 1.9 (0.4–5.5)
HPV 6 0 0.0 (0.0–2.3)
HPV 11 0 0.0 (0.0–2.3)
HPV 16 0 0.0 (0.0–2.3)
HPV 18 0 0.0 (0.0–2.3)
HPV 31 2 1.2 (0.2–4.5)
HPV 33 1 0.6 (0.0–3.5)
HPV 45 0 0.0 (0.0–2.3)
HPV 52 0 0.0 (0.0–2.3)
HPV 58 0 0.0 (0.0–2.3)
CI, confidence interval; HPV, human papillomavirus; N, number of subjects in the analysis popul
11, 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine.as HPV 31-, 33-, 45-, 52-, or 58-related lesions (94.7% and 93.9%, respec-
tively) amongwomen negative for the respective HPV types at baseline
(Table 5). Likewise, reductions in biopsy (94.5%) and definitive therapy
(96.2%) related to HPV 6, 11, 16, or 18 lesions were observed among
women negative for these types at baseline but positive for HPV 31,
33, 45, 52, or 58. Reductions in biopsy (93.5%) and definitive therapy
(93.0%) related to HPV 31-, 33-, 45-, 52-, or 58-positive lesionswere ob-
served among females positive at baseline for HPV 6, 11, 16, or 18.
4. Discussion
The 9vHPV vaccine demonstrated robust (N94%) direct protection
against cervical disease of any grade and, specifically, high-grade cervi-
cal disease, vulvar, and vaginal disease of any grade, condyloma, cervical
biopsy, and cervical definitive therapy procedures compared with the
historic placebo population among females negative for 14 HPV types.
This confirms the efficacy estimate previously published for the five
new vaccine types [7,8] and provides an estimate of 94.9–100% efficacy,
with respect to HPV 6, 11, 16, and 18, compared with an unvaccinated
population when the vaccine is delivered to young adolescent females.
The 9vHPV vaccine reduced the risk of therapeutic procedures
(97.8%) following detection of cervical abnormalities associated with
vaccine HPV types comparedwith unvaccinatedwomen. This reduction
is similar to the decrease in high-grade cervical disease observed with
9vHPV vaccination, suggesting that widespread 9vHPV vaccine dissem-
ination may substantially reduce surgical procedures and healthcare
utilization.
Among women positive for one or more HPV types at trial enroll-
ment, efficacy against other targeted HPV typeswasmaintained. Robust
efficacy (95.8–100%) was observed against cervical lesions (any grade
and high grade) and procedures caused by HPV 6, 11, 16, or 18 among
women negative for those types at baseline, regardless of baseline
HPV 31, 33, 45, 52, and 58 status. Similar results were observed
among women negative for HPV 31, 33, 45, 52, and 58, regardless of
HPV 6, 11, 16, or 18 status (91.1–95.1% efficacy against HPV 31-, 33-,
45-, 52-, and 58-related endpoints). These data support the potentialprocedures (subjects PCR-negative to 14 HPV types at baseline).
Historic placebo (N = 5887)
Reduction in incidence %
(95% CI)
Observed
cases
Incidence per 10,000 person-years
cases (95% CI)
5759
540 269.2 (246.9–292.8) 95.1 (92.6–97.0)
63 30.7 (23.6–39.3) 91.9 (78.7–97.3)
17 8.3 (4.8–13.2) 100 (71.1–100)
204 100.1 (86.8–114.8) 97.5 (93.6–99.2)
79 38.5 (30.5–48.0) 93.5 (83.5–97.8)
103 50.3 (41.0–61.0) 91.3 (82.3–96.0)
49 23.9 (17.7–31.6) 100 (91.1–100)
30 14.6 (9.9–20.8) 91.5 (68.9–98.6)
117 57.2 (47.3–68.5) 96.7 (90.7–99.1)
77 37.5 (29.6–46.9) 100 (93.9–100)
170 83.2 (71.1–96.6) 97.8 (93.4–99.4)
11 5.3 (2.7–9.6) 100 (57.5–100)
2 1.0 (0.1–3.5) 100 (−344.0–100)
91 44.4 (35.8–54.5) 100 (94.9–100)
25 12.2 (7.9–18.0) 100 (82.5–100)
39 19.0 (13.5–26.0) 93.4 (75.4–98.9)
15 7.3 (4.1–12.0) 91.5 (45.5–99.6)
7 3.4 (1.4–7.0) 100 (22.6–100)
37 18.0 (12.7–24.8) 100 (88.4–100)
27 13.1 (8.7–19.1) 100 (84.0–100)
ation; PCR, polymerase chain reaction; 9vHPV, nine-valent human papillomavirus (types 6,
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infected women.
The qHPV vaccine [10,11,19] and 9vHPV vaccine [7] are preventa-
tive, with no demonstrated efficacy against disease caused by an HPV
type present at the time of vaccination. Most prevalent HPV infections
in women aged 16–26 years (Supplementary Table S3) or 24–45 yearsTable 5
Effect of 9vHPV vaccine on the reduction in incidence of cervical, vulvar, and vaginal disease; c
population).
Endpoint Day 1 PCR-positive to ≥1 of the indicated
HPV types
Percen
[incide
HPV 6, 11, 16, or
18
HPV 31, 33, 45, 52, or
58
Related
Cervical disease, any grade
No
No
[1
Yes
[3.9
Yes
No
[511.9
Yes
[663.4 (
High-grade cervical disease
No
No
[
Yes
[3
Yes
No
[333.6
Yes
[455.2
Vulvar and vaginal disease, any
grade
No
No
[5
Yes
[11.
Yes
No
[102.6
Yes
[140.6
Vulvar and vaginal condyloma
No
No
[
Yes
[7.
Yes
No
[70.1
Yes
[102.4
High-grade vulvar and vaginal
disease
No
No
Yes
[
Yes
No
[
Yes
[2
Cervical biopsy
No
No
[6.9
Yes
[11.
Yes
No
[817.5
Yes [
Cervical definitive therapy
No
No
[
Yes
[3
Yes
No
[279.3
Yes
[276.4
CI, confidence interval; HPV, human papillomavirus; mITT, modified intention-to-treat; N, num
valent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58) recombinant vaccine.
a The percentage risk reduction in the 9vHPV vaccine group relative to historic placebo was c
placebo group).
b Estimated number of cases per 10,000 person-years of follow-up.[20] contain only one or two high-risk HPV types. Thus, HPV-infected,
sexually active women remain susceptible to new vaccine-preventable
HPV infections, as shown here and in previous analyses from qHPV vac-
cine trials [21].Moreover, long-term follow-up studies of vaccinated co-
horts demonstrate efficacy against disease occurrence following
treatment of dysplastic lesions, presumably through protection againstervical biopsy; and definitive therapy procedures stratified by baseline HPV status (mITT
t risk reductiona (95% CI)
nce rate (95% CI)b 9vHPV (N = 6997): historic placebo (N = 8748)]
to HPV 6, 11, 16, or 18 Related to HPV 31, 33, 45, 52, or 58
99.0 (96.4–99.8) 96.9 (93.4–98.7)
.1 (0.1–3.9): 106.4 (93.3–120.9)] [3.2 (1.2–7.0): 104.3 (91.3–118.6)]
97.4 (85.6–99.9) 18.9 (−4.8–37.7)
(0.1–22.0): 154.4 (110.8–209.5)] [420.9 (342.8–511.4): 519.1 (434.3–615.6)]
−2.2 (−32.7–20.7) 95.1 (81.9–99.1)
(423.0–614.0): 501.0 (416.7–597.3)] [8.3 (1.0–30.0): 168.3 (121.8–226.7)]
24.5 (−0.6–43.4) 13.3 (−15.0–35.4)
534.8–813.6): 879.1 (721.1–1061.3)] [682.3 (551.4–835.0): 787.0 (638.9–959.1)]
100 (96.1–100) 95.3 (88.4–98.4)
0.0 (0.0–2.0): 49.4 (40.6–59.6)] [2.1 (0.6–5.5): 45.8 (37.4–55.6)]
95.8 (76.9–99.8) 6.8 (−32.6–34.6)
.9 (0.1–22.0): 93.7 (60.6–138.3)] [254.2 (195.3–325.2): 272.7 (213.4–343.4)]
−2.3 (−40.9–25.8) 91.1 (67.5–98.5)
(264.1–415.8): 326.2 (259.8–404.3)] [8.3 (1.0–30.0): 93.4 (59.9–139.0)]
12.7 (−24.3–38.7) −14.4 (−67.3–21.4)
(352.0–579.1): 521.4 (404.9–661.0)] [462.9 (358.7–587.9): 404.5 (303.0–529.1)]
94.9 (90.6–97.4) 98.2 (90.5–99.9)
.3 (2.5–9.8): 103.1 (90.2–117.3)] [0.5 (0.0–3.0): 29.4 (22.7–37.4)]
92.4 (76.4–98.0) 51.1 (−27.5–83.1)
1 (2.3–32.4): 146.7 (105.3–199.0)] [26.1 (10.5–53.7): 53.3 (29.8–87.8)]
49.0 (18.6–69.3) 76.3 (−6.4–96.3)
(67.0–150.3): 201.3 (151.2–262.6)] [7.7 (0.9–27.7): 32.4 (14.8–61.4)]
43.1 (2.8–67.8) 9.7 (−156.7–68.2)
(89.2–211.0): 247.4 (173.3–342.5)] [53.4 (24.4–101.5): 59.2 (27.1–112.4)]
95.0 (90.5–97.9) 100 (91.0–100)
4.2 (1.8–8.4): 85.7 (74.0–98.8)] [0.0 (0.0–2.0): 20.0 (14.6–26.8)]
93.5 (75.9–98.9) 82.5 (−30.4–99.2)
4 (0.9–26.7): 113.9 (77.9–160.7)] [3.7 (0.1–20.6): 21.1 (7.8–46.0)]
61.4 (34.9–78.2) 82.3 (−32.4–99.2)
(41.6–110.9): 181.7 (134.4–240.2)] [3.8 (0.1–21.3): 21.5 (7.9–46.9)]
51.5 (11.6–74.8) −5.3 (−212.8–68.2)
(59.7–163.9): 211.3 (143.5–299.9)] [41.3 (16.6–85.2): 39.3 (14.4–85.4)]
100 (86.7–100) 100 (36.0–100)
[0.0 (0.0–2.0): 13.3 (9.0–19.0)] [0.0 (0.0–2.0): 3.6 (1.5–7.0)]
79.0 (−56.3–99.1) 65.0 (−217.8–98.6)
3.7 (0.1–20.6): 17.6 (5.7–41.0)] [3.7 (0.1–20.6): 10.5 (2.2–30.8)]
−544.6 (−∞–13.6) –
23.1 (8.5–50.3): 3.6 (0.1–20.0)] [3.8 (0.1–21.3): 0.0 (0.0–13.2)]
40.0 (−147.0–84.1) 9.9 (−398.1–83.7)
3.5 (6.4–60.1): 39.1 (14.4–85.2)] [17.6 (3.6–51.4): 19.5 (4.0–57.1)]
95.8 (92.9–97.8) 94.7 (91.6–97.0)
(3.7–11.8): 164.5 (148.2–182.0)] [9.1 (5.3–14.5): 172.4 (155.8–190.3)]
94.5 (84.0–98.6) −5.5 (−31.1–14.7)
1 (2.3–32.4): 203.5 (154.5–263.1)] [738.8 (630.4–860.5): 700.1 (601.6–810.2)]
−18.1 (−46.6–4.9) 93.5 (83.1–97.8)
(700.6–948.5): 692.5 (592.9–804.1)] [15.3 (4.2–39.2): 236.3 (182.8–300.6)]
0.4 (−27.1–21.7) 4.4 (−21.6–24.8)
1051.1 (881.3–1244.1): 1054.9
(883.9–1249.4)]
[1083.2 (910.7–1279.0): 1132.9
(954.8–1334.5)]
100 (96.8–100) 93.9 (86.4–97.4)
0.0 (0.0–2.0): 60.4 (50.8–71.4)] [3.2 (1.2–7.0): 52.1 (43.2–62.3)]
96.2 (78.7–99.8) 28.8 (−2.2–50.7)
.7 (0.1–20.6): 96.8 (64.3–139.9)] [185.1 (136.5–245.4): 259.8 (203.6–326.7)]
7.2 (−28.4–33.6) 93.0 (74.3–98.8)
(217.3–353.4): 301.0 (239.4–373.6)] [7.6 (0.9–27.6): 109.3 (74.3–155.1)]
44.4 (18.1–62.7) 34.2 (4.0–55.1)
(200.9–371.1): 497.0 (388.9–625.9)] [316.3 (234.8–417.0): 480.6 (374.6–607.2)]
ber of subjects in the analysis population; PCR, polymerase chain reaction; 9vHPV, nine-
alculated as 100% × (1− incidence rate in 9vHPV vaccine group/incidence rate in historic
116 A.R. Giuliano et al. / Gynecologic Oncology 154 (2019) 110–117subsequent infection with a vaccine-related HPV type [22–25]. True
long-term protection against disease in sexually active women
(includingwomen N26 years of age [20])may be greater than originally
estimated from trials, where cases were censored after the first disease
occurrence. Effectiveness studies conducted among populations where
vaccine uptake is high (e.g. N80%) are needed to assess the full popula-
tion impact of the vaccine.
The 9vHPV vaccine protects against disease related to the HPV
types most commonly associated with high-grade intraepithelial
neoplasia and cancer. In contrast, no efficacy was observed against
non-vaccine HPV types 35, 39, 51, 56, and 59 [7]. Although these
HPV types can cause high-grade cervical disease, they are not com-
monly found in cervical cancer [1,4,26,27]. However, as they cause
~10% of cervical cancers worldwide, which may develop later in life
than HPV 16- and 18-related cancers [1], screening algorithms to
prevent these cancers are needed.
Recent publications have raised the prospect of changing screening
procedures and guidelines in HPV-vaccinated populations [28]. Our
results indicate the 9vHPV vaccine can reduce rates of cervical
abnormalities. As shown in the ATHENA trial [26] and prospective
studies [29], the absolute risk of developing CIN 3 is highest among
women positive for HPV 16, 18, 31, 33, 45, and 52-types against which
the 9vHPV vaccine offers direct protection. Among populations
vaccinated with 9vHPV vaccine, the expected reduction in circulating
HPV types that cause the majority of anogenital disease and associated
procedures should bolster the argument to reconsider current screen-
ing. The 9vHPV vaccine efficacy estimates presented here may be
useful in modeling the age at screening initiation and the screening in-
terval, informing development of simplified cervical cancer screening
policies.
This study included a diverse population across world regions
and demographic characteristics. The trials utilized common proto-
cols, eligibility criteria, case definition, pathology panel adjudication,
PCR assays, and colposcopy standardization, minimizing variability
in exposure and endpoint assessment. All participants were inten-
sively screened throughout several years, with rigorous assessment
of disease endpoints and procedures. Although there is much
strength to this analysis, there are limitations that should be noted.
Ethical considerations precluded use of a placebo group in the
9vHPV program, hence the reliance on historic placebo populations.
Given the similar eligibility criteria across the qHPV and 9vHPV vac-
cine trials, placebo and vaccinated cohorts were similar on key char-
acteristics; thus, biases due to differences in sexual history and
baseline HPV status were minimized. A comparison of Pap test ab-
normalities with historic placebo could not be rigorously performed,
as HPV-type attribution, which is based on HPV typing of cervical
swab samples, in the historic placebo groups for HPV 31, 33, 45, 52,
and 58 in FUTURE I and II were performed only in a limited fashion.
Prior reports indicate the qHPV vaccine reduces HPV 16- and 18-
related Pap test abnormalities by N90% [16], and the 9vHPV vaccine
reduces abnormalities due to HPV 31, 33, 45, 52, and 58 by N90%
(versus qHPV vaccine) [8].
Overall, 9vHPV vaccination significantly reduces genital disease
caused by the targetedHPV types comparedwith a population of unvac-
cinated women. If the 9vHPV vaccine is broadly disseminated, the bur-
den of genital diseases is likely to dramatically decrease. While early
vaccination in HPV-naïve persons is optimal, adult and sexually active
personsmay benefit from vaccination, supporting broad catch-up vacci-
nation programs.
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